First Time Loading...

Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 1.77 USD 1.14% Market Closed
Updated: May 15, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Cash Flow Statement

-188.6m
+2%
Operating Cash Flow
Growth Rates:
1 Year
+29%
3 Years
+40%
5 Years
-
7 Years
-47%
10 Years
-201%
118.2m
-15%
Investing Cash Flow
Growth Rates:
1 Year
-57%
3 Years
-62%
5 Years
-
7 Years
-
10 Years
-
42m
+140 010%
Financing Cash Flow
Growth Rates:
1 Year
+6 906%
3 Years
-
5 Years
-95%
7 Years
-80%
10 Years
-65%

Cash Flow Statement
Nektar Therapeutics

Rotate your device to view
Cash Flow Statement
Currency: USD
Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024
Operating Cash Flow
Net Income
(153)
(143)
(56)
(54)
26
6
(73)
(81)
(135)
(131)
(166)
(154)
(198)
(209)
(105)
(97)
(129)
903
746
681
659
(423)
(425)
(441)
(461)
(431)
(441)
(444)
(429)
(474)
(495)
(524)
(491)
(525)
(454)
(368)
(415)
(307)
(294)
(276)
(176)
Depreciation & Amortization
14
14
13
13
13
12
12
13
14
15
15
15
16
16
16
15
13
12
10
11
12
12
13
13
15
15
15
14
13
14
14
14
14
14
13
13
12
10
9
8
7
Change in Deffered Taxes
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
1
1
1
(0)
2
Stock-Based Compensation
18
18
17
17
18
18
19
20
21
23
24
26
28
30
32
37
48
61
75
88
94
97
99
100
100
99
97
94
93
93
94
95
92
79
67
57
46
43
39
33
0
Other Non-Cash Items
88
86
13
15
16
17
87
30
29
26
25
13
14
18
20
39
52
59
70
65
66
71
73
77
100
105
110
100
84
85
90
120
79
114
86
48
150
98
103
96
3
Cash Taxes Paid
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
0
0
(3)
(3)
3
0
Cash Interest Paid
17
17
17
17
17
17
17
20
18
22
20
21
21
20
20
20
20
20
20
20
19
19
19
19
19
19
15
10
5
0
0
0
0
0
0
0
0
0
0
0
0
Change in Working Capital
(11)
6
(34)
(116)
(71)
(90)
(49)
(35)
(68)
(37)
(15)
8
40
3
17
(38)
(34)
(53)
(70)
(39)
(47)
16
18
22
21
(44)
(24)
17
20
65
32
(23)
(26)
(19)
(43)
1
(16)
(46)
(23)
(20)
(25)
Cash from Operating Activities
(63)
N/A
(38)
+40%
(64)
-70%
(142)
-123%
(16)
+88%
(55)
-232%
(23)
+59%
(73)
-223%
(160)
-119%
(127)
+21%
(140)
-10%
(117)
+16%
(128)
-9%
(173)
-35%
(52)
+70%
(80)
-53%
(98)
-22%
920
N/A
755
-18%
718
-5%
690
-4%
(324)
N/A
(321)
+1%
(329)
-2%
(326)
+1%
(356)
-9%
(340)
+4%
(313)
+8%
(312)
+0%
(311)
+0%
(360)
-16%
(413)
-15%
(424)
-3%
(416)
+2%
(398)
+4%
(304)
+24%
(268)
+12%
(244)
+9%
(203)
+17%
(193)
+5%
(189)
+2%
Investing Cash Flow
Capital Expenditures
(8)
(9)
(9)
(10)
(7)
(9)
(13)
(11)
(12)
(10)
(6)
(6)
(9)
(10)
(10)
(10)
(7)
(7)
(8)
(14)
(19)
(28)
(31)
(26)
(22)
(13)
(9)
(7)
(9)
(10)
(11)
(15)
(16)
(14)
(11)
(6)
(2)
(1)
(1)
(1)
(1)
Other Items
(44)
(85)
(86)
(28)
80
12
(19)
(3)
(19)
40
59
(76)
(123)
(75)
(184)
(19)
39
(897)
(1 437)
(1 366)
(1 421)
(493)
190
233
438
561
548
504
318
235
186
218
339
348
457
372
278
219
163
140
119
Cash from Investing Activities
(52)
N/A
(93)
-79%
(95)
-2%
(38)
+60%
74
N/A
3
-97%
(32)
N/A
(14)
+55%
(31)
-119%
30
N/A
53
+76%
(82)
N/A
(132)
-60%
(85)
+36%
(194)
-129%
(29)
+85%
33
N/A
(904)
N/A
(1 445)
-60%
(1 380)
+4%
(1 440)
-4%
(521)
+64%
159
N/A
207
+30%
417
+101%
549
+32%
539
-2%
496
-8%
309
-38%
225
-27%
175
-22%
203
+16%
323
+59%
334
+3%
446
+34%
366
-18%
276
-25%
217
-21%
162
-25%
140
-14%
118
-15%
Financing Cash Flow
Net Issuance of Common Stock
129
130
136
164
44
47
46
32
37
34
35
210
215
222
224
60
82
883
877
852
823
19
21
23
30
30
26
23
29
33
34
33
16
5
3
1
1
0
0
0
27
Net Issuance of Debt
(3)
(3)
(3)
(4)
(4)
(4)
(5)
236
236
235
235
(6)
(5)
(4)
(3)
(5)
(5)
(4)
(3)
0
0
0
0
0
0
(250)
(250)
(250)
0
0
0
0
0
0
0
0
0
0
0
0
0
Other
(7)
(7)
(7)
(7)
0
0
0
(138)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
146
147
148
149
3
3
2
2
1
0
0
0
0
15
Cash from Financing Activities
119
N/A
120
+1%
125
+4%
153
+22%
40
-74%
42
+7%
42
-2%
131
+214%
135
+3%
132
-2%
132
+0%
204
+54%
210
+3%
218
+4%
221
+1%
54
-75%
78
+43%
879
+1 033%
874
-1%
852
-2%
823
-3%
19
-98%
21
+12%
23
+11%
30
+26%
(220)
N/A
(224)
-2%
(80)
+64%
(74)
+8%
181
N/A
183
+1%
36
-80%
19
-47%
8
-60%
4
-49%
2
-62%
1
-60%
0
-83%
0
N/A
0
-70%
42
+140 010%
Change in Cash
Effect of Foreign Exchange Rates
0
0
0
(0)
(0)
(0)
(0)
(0)
(0)
(0)
0
(0)
0
0
(0)
0
(0)
0
(0)
(0)
0
(0)
(0)
(0)
(0)
(0)
0
0
0
0
(0)
(0)
(0)
(0)
(0)
(0)
(0)
0
0
0
0
Net Change in Cash
4
N/A
(11)
N/A
(34)
-207%
(27)
+20%
97
N/A
(10)
N/A
(13)
-36%
43
N/A
(57)
N/A
35
N/A
45
+29%
4
-91%
(49)
N/A
(40)
+20%
(25)
+36%
(55)
-116%
11
N/A
895
+7 753%
184
-79%
190
+3%
72
-62%
(826)
N/A
(141)
+83%
(99)
+30%
120
N/A
(27)
N/A
(25)
+8%
103
N/A
(77)
N/A
94
N/A
(2)
N/A
(174)
-9 047%
(82)
+53%
(75)
+9%
52
N/A
63
+22%
9
-86%
(27)
N/A
(41)
-53%
(53)
-30%
(28)
+47%
Free Cash Flow
Free Cash Flow
(71)
N/A
(46)
+35%
(73)
-58%
(152)
-110%
(23)
+85%
(64)
-178%
(35)
+45%
(84)
-139%
(172)
-104%
(136)
+21%
(146)
-7%
(123)
+15%
(137)
-11%
(182)
-33%
(62)
+66%
(90)
-44%
(105)
-16%
913
N/A
747
-18%
704
-6%
671
-5%
(352)
N/A
(352)
0%
(355)
-1%
(348)
+2%
(369)
-6%
(349)
+5%
(321)
+8%
(322)
0%
(321)
+0%
(371)
-15%
(428)
-15%
(440)
-3%
(430)
+2%
(409)
+5%
(310)
+24%
(269)
+13%
(245)
+9%
(204)
+17%
(193)
+5%
(189)
+2%

See Also

Summary
NKTR intrinsic value, competitors valuation, and company profile.
DCF Valuation
NKTR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NKTR stock valuation using valuation multiples.
Wall Street Estimates
NKTR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NKTR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.